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Objectives: Patients with acute myelocytic leukemia (AML) with favorable cytogenetics such as t(8;21) and inv(16) are classified as good risk group and are not subject to hematopoietic stem cell transplantation (HSCT) frontline. However there are limited data following HSCT in relapsed good risk AML. Since allogeneic HSCT has been regarded traditionally as the only curative option in this population, we evaluated the outcomes of the patients who were treated with allogeneic HSCT in relapsed good risk AML carrying inv(16) or t(8:21).
Methods: We evaluated the outcomes of 22 consecutive patients who underwent allogeneic HSCT with either myeloablative (n 5 17) or reduced-intensity conditioning (RIC) regimen (n 5 5) between January 1997 and May 2007 at Seoul National University Hospital.
Results: Among 22 patients (median age 33, 18-70), 13 patients were classified as AML with t(8;21), 9 patients as AML with inv(16). 13 patients received sibling donor transplantation and the remaining 9 patients received unrelated donor transplantation. Median follow up duration was 8.3 months (range: 5.9 -10.7 months). 20 patients attained remission after HSCT and 10 patients relapsed after remission with HSCT, 8 (61.5%) with t(8;21) and 2 (22.2%) with inv(16). At the time of analysis, only 7 patients are alive (3 patients (23%) with t(8;21), 4 patients (44%) with inv(16). 2 patients with inv(16) were lost to follow up. 13 patients (61.5%) expired, 10 with t(8;21) and 3 with inv(16). 9 patients with myeloablative conditioning regimen and 4 patients with RIC regimen expired. There was no statistical difference between the myeloablative and RIC regimen groups (p 5 .14). The main causes of death were relapse (53.8%, 7 patients), infection (23%, 3 patients) and GVHD (23%, 3 patients). 3-year survival rate was 43.8%. However, in patients with t(8;21) AML (n 5 13), 3-year survival rate was 28.7%. On the contrary, in patients with inv(16) AML (n 5 9), 3-year survival rate was 65.8%.
Conclusion: Patients with relapsed favorable risk AML showed divergent outcomes after allogeneic HSCT according to cytogenetic abnormalities. Patients with relapsed t(8;21) AML particularly exhibited high relapse rate and poor prognosis after allogeneic HSCT which is similar to treatment outcome of poor risk group AML. New treatment approaches including frontline HSCT with either allogeneic or autologous approaches should be tried in a prospective setting in this population.
ROLE OF ANTI THYMOCYTE GLOBULIN (ATG) PRIOR TO UNRELATED DONOR STEM CELL TRANSPLANTATION (URD SCT) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE
Ganguly, S., Koya, B., Divine, C., Abhyankar, S., Aljitawi, O., DeaunaLimayo, D., Bodensteiner, D.C., Skikne, B.S., McGuirk, J.L. University of Kansas Medical Center, Kansas City, KS Introduction: Long-term outcome in patients undergoing URD SCT depends partly upon the balance between complications from graft versus host disease (GVHD) and graft versus leukemia (GVL) effect. Use of ATG prior to URD SCT in an attempt to decrease the incidence and severity of GVHD may actually increase the risk of relapse secondary to reduced GVL effect.
Methods: In an attempt to examine whether addition of ATG provides long-term disease control in patients with hematologic malignancies undergoing URD SCT, we retrospectively evaluated our experience and analyzed the outcomes of URD SCT with or without ATG in patients with hematologic malignancies from 1995 to 2007. Fisher's exact test with two-tailed comparison was used for statistical purposes.
Results: Forty-six males and 22 females (n 5 68) of median age 47 years (range: 15-64 years) were treated. Most common indication of transplantation was AML (n 5 28) followed by CML (n 5 12) and NHL (n 5 12). Twenty-eight patients received ATG based regimen. Sixty-two of 68 patients engrafted (91%). Median time for neutrophil recovery was 15 days. There was no difference in the engraftment kinetics between ATG and non-ATG group of patients. Seventeen (25%) patients died within 100 days of transplantation. Median duration of follow-up was 12.6 months (range: 7-1026 days). Overall, 37 patients (53%) of this cohort died after transplantation. Of all the patients that died, 11 (39%) received ATG and 26 patients (65%) did not receive ATG (p\0.05). Infection was the commonest cause of mortality (n 5 15; Five in the ATG group and 10 in non-ATG group; p 5 0.5). Graft versus host disease was the direct cause of death in 6 patients (3 of them had received ATG) and 6 patients died from relapse of their disease (3 patients received ATG). These differences were not statistically significant (p 5 0.6). Overall survival (OS) of all patients was 50% at 1 year and 47% at 4 years. There was no difference in the OS at 1-year between the ATG (64%) and non-ATG groups (40%) (p 5 0.08), whereas at 4 years, OS in the ATG (60%) was superior to the non-ATG group (35%) (p\0.05).
Conclusion: Patients who received ATG as a part of the preparative regimen prior to URD SCT seemed to have a better long-term survival compared to patients that did not receive ATG. Use of ATG did not have any impact on relapse, infection rate or GVHD related mortality.
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